KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing.

@article{French2011KRASMD,
  title={KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing.},
  author={Deborah L. French and Andrew D Smith and Martin P Powers and Alan H. B. Wu},
  journal={Clinica chimica acta; international journal of clinical chemistry},
  year={2011},
  volume={412 17-18},
  pages={1578-81}
}
BACKGROUND Binding of a ligand to the epidermal growth factor receptor (EGFR) stimulates various intracellular signaling pathways resulting in cell cycle progression, proliferation, angiogenesis and apoptosis inhibition. KRAS is involved in signaling pathways including RAF/MAPK and PI3K and mutations in this gene result in constitutive activation of these pathways, independent of EGFR activation. Seven mutations in codons 12 and 13 of KRAS comprise around 95% of the observed human mutations… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…